EXPLORE THE SCIENCE
TL;DR: A 2026 review in Brain Medicine found mixed randomized-trial evidence for creatine monohydrate as an add-on depression treatment: 2 of 5 trials showed symptom benefits, while 3 did not find a clear advantage. Key Findings Five randomized trials were rev…
Read article
TL;DR: A 2026 systematic review and meta-analysis in Brain, Behavior, & Immunity – Health found that adding celecoxib to antidepressants was linked to lower depressive symptom scores in 7 small trials, but the efficacy evidence was rated very low certainty. Ke…
Read article
TL;DR: A 2026 study in BJPsych Open found that closely monitored antidepressant care improved quality of life and reduced societal costs in both PReDicT and usual-care groups, while the PReDicT algorithm added uncertain, country-dependent economic value. Key F…
Read article
TL;DR: A 2026 study in The Pharmacogenomics Journal tested pharmacogenomic (PGx) depression care, meaning medication guidance based on drug-gene interactions; targeting Veterans already taking antidepressants with common PGx interactions raised the actionable-…
Read article
TL;DR: A 2026 retrospective case series study in European Journal of Psychotraumatology found that trauma flashbacks during esketamine nasal spray sessions were distressing but usually time-limited in 22 patients with treatment-resistant depression and PTSD; w…
Read article
When Depression Threatens Pregnancy: A 34% Elevated Miscarriage Risk TL;DR: Untreated depression increases miscarriage risk by 34% across nearly 9 million women, but antidepressants reduce that risk to 24%—meaning the medication is safer than the disease durin…
Read article
How Ketamine Rewires Receptors to Beat Depression TL;DR: Using PET imaging to directly visualize AMPA receptors in the living human brain, researchers discovered that ketamine’s rapid antidepressant effect works by reshuffling these receptors across specific b…
Read article
How Scientists Turned a Brief Ketamine High into a Two-Month Antidepressant Effect TL;DR: Blocking DUSP6 protein alongside ketamine extends antidepressant effects from 2 weeks to 4+ weeks in mice, potentially offering single-dose treatment instead of repeated…
Read article
The NLRP3 inflammasome is increasingly being recognized as a mediator between inflammation and depression. Targeting this molecular complex shows promise for developing new antidepressant therapies. Key Facts: The NLRP3 inflammasome is made up of NLRP3, ASC, a…
Read article
A new study published in Frontiers in Psychiatry provides promising evidence that focused ultrasound stimulation of the prefrontal cortex can alleviate depressive behaviors in mice by suppressing inflammatory responses. Key facts: Researchers stimulated the pr…
Read article